You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

PD-L1 (receptor blocking antibody)

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Cancer, Tumors, Tumor Trial in Worldwide (BMS-986226, Nivolumab, Ipilimumab)

Completed
  • Cancer
  • +3 more
  • Boston, Massachusetts
  • +12 more
Mar 11, 2022

Solid Tumor, Adult, EphA2 Overexpression, KRAS G12V Trial in Beijing (KRAS-EphA-2-CAR-DC, Abraxane, Cyclophosphamide)

Recruiting
  • Solid Tumor, Adult
  • +4 more
  • KRAS-EphA-2-CAR-DC
  • +3 more
  • Beijing, Beijing, China
    Biotherapeutic Department of Chinsese PLA Gereral Hospital
Nov 29, 2022

Solid Tumor, Adult, Lymphoma, EphA2 Overexpression Trial in Beijing (TP53-EphA-2-CAR-DC, Abraxane, Cyclophosphamide)

Recruiting
  • Solid Tumor, Adult
  • +6 more
  • TP53-EphA-2-CAR-DC
  • +3 more
  • Beijing, Beijing, China
    Biotherapeutic Department of Chinsese PLA Gereral Hospital
Nov 29, 2022

Biliary Tract Cancer, Candonilimab, Claudin 18.2 Trial in Shanghai (cardonilizumab, LM-302)

Recruiting
  • Biliary Tract Cancer
  • +2 more
  • Shanghai, China
    Zhongshan hospital, Fudan University
Aug 12, 2023

Advanced Lung Carcinoma Trial in Beijing (LK101 injection (personlized neoantigen pulsed DC vaccine ), Pembrolizumab,

Recruiting
  • Advanced Lung Carcinoma
  • LK101 injection (personlized neoantigen pulsed DC vaccine )
  • +2 more
  • Beijing, Beijing, China
    Cancer hospital Chinese Academy of Medical Sciences
May 23, 2023

Solid Advanced Tumor, Lymphoma Trial in Belgium, France (OSE-279 100mg, OSE-279 300mg, OSE-279 500mg)

Recruiting
  • Solid Advanced Tumor
  • Lymphoma
  • OSE-279 100mg
  • +2 more
  • Anderlecht, Belgium
  • +5 more
Feb 27, 2023

Hepatocellular Carcinoma (HCC) Trial in Nancy, Paris (Pexastimogene Devacirepvec (Pexa Vec), Nivolumab)

Terminated
Has Results
  • Hepatocellular Carcinoma (HCC)
  • Nancy, France
  • +1 more
Oct 21, 2021

PD-1 Antibody, Hemophagocytic Lymphohistiocytosis, Epstein-Barr Virus Trial in Beijing (L-DEP and PD-1 antibody)

Not yet recruiting
  • PD-1 Antibody
  • +3 more
  • L-DEP and PD-1 antibody
  • Beijing, Beijing, China
    Beijing Friendship Hospital, Capital Medical University
Mar 8, 2023

Angiogenesis Inhibitor Plus Anti-PD-1/PD-L1 Antibody in Advanced

Recruiting
  • Esophageal Neoplasms
  • an anti-PD-1/PD-L1 antibody plus an angiogenesis inhibitor
  • Zhengzhou, Henan, China
    The First Affiliated Hospital of Zhengzhou University
Apr 21, 2022

Advanced Solid Tumor, Refractory Tumor Trial in Suzhou (Thymalfasin, Radiotherapy, PD-1/PD-L1 inhibitor)

Recruiting
  • Advanced Solid Tumor
  • Refractory Tumor
  • Suzhou, China
    The Second Affiliated Hospital of SchoowUniversity
Mar 29, 2023

Malignant Tumor Trial in Shanghai (PM8002)

Recruiting
  • Malignant Neoplasm
  • Shanghai, Shanghai, China
    Shanghai Orient Hospital
Jun 25, 2023

Oesophageal Squamous Cell Carcinoma Trial in Shanghai (PD-L1 Antibody SHR-1316)

Recruiting
  • Oesophageal Squamous Cell Carcinoma
  • PD-L1 Antibody SHR-1316
  • Shanghai, China
    180 Fenglin Road
Jun 12, 2022

NSCLC (NSCLC) Trial in Shanghai (Tumor treating fields(EFE-P100), Docetaxel injection)

Not yet recruiting
  • Non-small Cell Lung Cancer (NSCLC)
  • Tumor treating fields（EFE-P100）
  • Docetaxel injection
  • Shanghai, China
    Shanghai Pulmonary Hospital
Dec 21, 2022

Nasopharyngeal Carcinoma Trial in Guangzhou (BL-B01D1, capecitabine, gemcitabine)

Not yet recruiting
  • Nasopharyngeal Carcinoma
  • Guangzhou, Guangdong, China
    Sun Yat-sen University Cancer Center
Oct 31, 2023

Combined HAIC, TKI/Anti-VEGF and ICIs as Conversion Therapy for

Recruiting
  • Hepatocellular Carcinoma Non-resectable
  • HAIC
  • +8 more
  • Quanzhou, Fujian, China
  • +1 more
Jan 26, 2023

Breast Cancer Trial in Guangzhou (Chidamide Plus Toripalimab Plus Paclitaxel)

Recruiting
  • Breast Cancer
  • Chidamide Plus Toripalimab Plus Paclitaxel
  • Guangzhou, Guangdong, China
    Sun Yat-sen University Cancer Center
Feb 19, 2023

NSCLC Trial in Saint Petersburg, Cremona, Vilnius (REGN2810/ipi, REGN2810/chemo/ipi, Pembrolizumab)

Terminated
Has Results
  • Non-small Cell Lung Cancer
  • Saint Petersburg, Florida
  • +2 more
Oct 22, 2022

Combined TACE, TKI/Anti-VEGF and ICIs as Conversion Therapy for

Recruiting
  • Hepatocellular Carcinoma Non-resectable
  • TACE
  • +8 more
  • Quanzhou, Fujian, China
  • +3 more
Jan 29, 2023

Solid Tumor Trial (IN10018, Nab-paclitaxel, Tislelizumab)

Not yet recruiting
  • Solid Tumor
  • (no location specified)
Aug 1, 2023

Advanced Solid Tumor, NSCLC, Small Cell Lung Cancer Trial (IMM2520)

Not yet recruiting
  • Advanced Solid Tumor
  • +5 more
  • (no location specified)
Mar 20, 2023

HIV Trial (ASC22 group)

Not yet recruiting
  • HIV Infections
  • ASC22 group
  • (no location specified)
Mar 4, 2022

Non Small Cell Lung Cancer Trial in Davis, Orlando, Columbus (ONC-392, Docetaxel)

Not yet recruiting
  • Non Small Cell Lung Cancer
  • Davis, California
  • +2 more
Jan 5, 2023

Colorectal Cancer Stage IV, Mismatch Repair-deficient (dMMR), Microsatellite Instability-high (MSI-H) Trial (Cadonilimab)

Not yet recruiting
  • Colorectal Cancer Stage IV
  • +2 more
  • (no location specified)
Jun 19, 2022

Unresectable Hepatocellular Carcinoma Trial (Huaier granule, Atezolizumab + Bevacizumab, Camrelizumab+Apatinib)

Not yet recruiting
  • Unresectable Hepatocellular Carcinoma
  • Huaier granule
  • +3 more
  • (no location specified)
Dec 20, 2022

Advanced Urothelial Carcinoma Trial in Beijing (anti-PD-L1 antibody, albumin bound paclitaxel)

Active, not recruiting
  • Advanced Urothelial Carcinoma
  • anti-PD-L1 antibody
  • albumin bound paclitaxel
  • Beijing, Beijing, China
    Beijing Tumor Hospital
Jan 20, 2022